{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T20:59:11Z","timestamp":1774126751111,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010878","name":"AbbVie Biotherapeutics","doi-asserted-by":"publisher","award":["1"],"award-info":[{"award-number":["1"]}],"id":[{"id":"10.13039\/100010878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12325-019-01012-6","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T19:33:38Z","timestamp":1561491218000},"page":"2475-2486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections"],"prefix":"10.1007","volume":"36","author":[{"given":"Tania M.","family":"Welzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Sajeev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaozhu J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Pinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-6062","authenticated-orcid":false,"given":"Yanjun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"key":"1012_CR1","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","volume":"385","author":"DP Webster","year":"2015","unstructured":"Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124\u201335.","journal-title":"Lancet"},{"key":"1012_CR2","unstructured":"Tyagi I, Koirala J. Hepatitis C. Treasure Island: StatPearls. \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430897\/\n                    \n                  . Accessed Sep 2018."},{"key":"1012_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.7326\/M13-1133","volume":"160","author":"MM Denniston","year":"2014","unstructured":"Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293\u2013300.","journal-title":"Ann Intern Med"},{"key":"1012_CR4","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","volume":"150","author":"Z Younossi","year":"2016","unstructured":"Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150:1599\u2013608.","journal-title":"Gastroenterology"},{"key":"1012_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12879-015-0748-8","volume":"15","author":"J Smith-Palmer","year":"2015","unstructured":"Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19.","journal-title":"BMC Infect Dis"},{"key":"1012_CR6","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1016\/j.jhep.2016.08.001","volume":"65","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Hassanein TI. Management of the patient with SVR. J Hepatol. 2016;65:S120\u20139.","journal-title":"J Hepatol"},{"key":"1012_CR7","first-page":"316","volume":"42","author":"T Kish","year":"2017","unstructured":"Kish T, Aziz A, Sorio M. Hepatitis C in a new era: a review of current therapies. Pharm Ther. 2017;42:316\u201329.","journal-title":"Pharm Ther"},{"key":"1012_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.2014.7085","volume":"312","author":"A Kohli","year":"2014","unstructured":"Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312:631\u201340.","journal-title":"JAMA"},{"key":"1012_CR9","doi-asserted-by":"publisher","first-page":"e1004854","DOI":"10.1371\/journal.ppat.1004854","volume":"11","author":"SM Horner","year":"2015","unstructured":"Horner SM, Naggie S. Successes and challenges on the road to cure hepatitis C. PLoS Pathog. 2015;11:e1004854.","journal-title":"PLoS Pathog"},{"key":"1012_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, et al. Glecaprevir\u2013pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354\u201369.","journal-title":"N Engl J Med"},{"key":"1012_CR11","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062\u20138.","journal-title":"Lancet Infect Dis"},{"key":"1012_CR12","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608\u201317.","journal-title":"N Engl J Med"},{"key":"1012_CR13","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599\u2013607.","journal-title":"N Engl J Med"},{"key":"1012_CR14","doi-asserted-by":"crossref","unstructured":"D\u2019Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70(3):379\u201387.","DOI":"10.1016\/j.jhep.2018.11.011"},{"key":"1012_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jhep.2018.09.018","volume":"70","author":"PS Belperio","year":"2019","unstructured":"Belperio PS, Shahoumian TA, Loomis TP, Mole LA, Backus LI. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir\/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol. 2019;70:15\u201323.","journal-title":"J Hepatol"},{"key":"1012_CR16","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jval.2016.04.007","volume":"19","author":"A Muhlbacher","year":"2016","unstructured":"Muhlbacher A, Bethge S. First and foremost battle the virus: eliciting patient preferences in antiviral therapy for hepatitis C using a discrete choice experiment. Value Health. 2016;19:776\u201387.","journal-title":"Value Health"},{"key":"1012_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16:3\u201313.","journal-title":"Value Health"},{"key":"1012_CR18","unstructured":"FDA. Advancing use of patient preference information as scientific evidence in medical product evaluation. \n                    https:\/\/www.fda.gov\/ScienceResearch\/SpecialTopics\/RegulatoryScience\/ucm574320.htm\n                    \n                  . Accessed Sep 2018."},{"key":"1012_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marschal D, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14:403\u201313.","journal-title":"Value Health"},{"key":"1012_CR20","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/j.1475-6773.2005.00438.x","volume":"40","author":"JH Hibbard","year":"2005","unstructured":"Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short form of the patient activation measure. Health Serv Res. 2005;40:1918\u201330.","journal-title":"Health Serv Res"},{"key":"1012_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.1475-6773.2004.00269.x","volume":"39","author":"JH Hibbard","year":"2004","unstructured":"Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39:1005\u201326.","journal-title":"Health Serv Res"},{"key":"1012_CR22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jval.2016.02.019","volume":"19","author":"M Ho","year":"2016","unstructured":"Ho M, Saha A, McCleary KK, et al. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies. Value Health. 2016;19:746\u201350.","journal-title":"Value Health"},{"key":"1012_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/MEG.0000000000000858","volume":"29","author":"F Su","year":"2017","unstructured":"Su F, Beste LA, Green PK, Berry K, Ioannou GN. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17,487 patients. Eur J Gastroenterol Hepatol. 2017;29:686\u201393.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1012_CR24","doi-asserted-by":"publisher","first-page":"e0179764","DOI":"10.1371\/journal.pone.0179764","volume":"12","author":"O Dalgard","year":"2017","unstructured":"Dalgard O, Weiland O, Noraberg G, et al. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections\u2014a Scandinavian real-life study. PLoS One. 2017;12:e0179764.","journal-title":"PLoS One"},{"key":"1012_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40271-016-0207-7","volume":"10","author":"DM Evon","year":"2017","unstructured":"Evon DM, Golin CE, Stoica T, et al. What\u2019s important to the patient? Informational needs of patients making decisions about hepatitis C treatment. Patient. 2017;10:335\u201344.","journal-title":"Patient"},{"key":"1012_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12876-015-0356-5","volume":"15","author":"JL Zuchowski","year":"2015","unstructured":"Zuchowski JL, Hamilton AB, Pyne JM, et al. Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment. BMC Gastroenterol. 2015;15:124.","journal-title":"BMC Gastroenterol"},{"key":"1012_CR27","first-page":"265","volume":"5","author":"TL Kauf","year":"2012","unstructured":"Kauf TL, Mohamed AF, Hauber AB, Fetzer D, Ahmad A. Patients\u2019 willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection. Patient. 2012;5:265\u201378.","journal-title":"Patient"},{"key":"1012_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-016-0763-8","volume":"18","author":"AC Muhlbacher","year":"2017","unstructured":"Muhlbacher AC, Bridges JF, Bethge S, et al. Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment. Eur J Health Econ. 2017;18:155\u201365.","journal-title":"Eur J Health Econ"},{"key":"1012_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1086\/595685","volume":"48","author":"VL Re","year":"2009","unstructured":"Re VL, Amorosa VK, Localio AR, et al. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis. 2009;48:186\u201393.","journal-title":"Clin Infect Dis"},{"key":"1012_CR30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3350\/kjhep.2009.15.3.338","volume":"15","author":"SW Jeong","year":"2009","unstructured":"Jeong SW, Kim JD, Woo HY, et al. Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response. Korean J Hepatol. 2009;15:338\u201349.","journal-title":"Korean J Hepatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01012-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01012-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01012-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T23:11:04Z","timestamp":1592953864000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01012-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1012"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01012-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]},"assertion":[{"value":"3 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}